SEC Form 4 · accession 0000899243-19-006307

Global Blood Therapeutics, Inc. · GBT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks

Period of report

Mar 1, 2019

Accepted (ET)

Mar 5, 2019 · 8:47 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001629137

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F2	$53.48	Mar 1, 2019	A	45,000	A	—	Feb 28, 2029	Common Stock	45,000	45,000	D
Restricted Stock Units^F1,F3	—	Mar 1, 2019	A	30,000	A	—	—	Common Stock	30,000	30,000	D

F1Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2The shares of Common Stock underlying the option shall vest with respect to 1/4th of the shares on February 25, 2020 and thereafter 1/12th of the remaining underlying shares shall vest in equal quarterly installments over 3 years from February 25, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F3The shares of Common Stock underlying the RSUs shall vest with respect to 1/4th of the shares on March 1, 2020 and thereafter 1/6th of the remaining underlying shares shall vest in semi-annual installments over 3 years from March 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Chief Scientific Officer